This Section carries out both basic and clinical research on the biological role and mechanisms of action of peptide growth factors such as insulin-like growth factors-I and -II (IGFs-I and -II) in embryonic development and reproduction. These particular growth factors have critical roles in development as proven by the fact that targeted deletion of IGF-I or IGF-II gene expression results in dwarfism and infertility - although how IGF deletion causes these defects is not yet understood. Molecular, immunological and radioligand probes are used to analyze the cellular sites of synthesis and action of these growth factors during embryonic development as well as in different physiological and pathophysiological situations in which IGFs have key roles. This Section has made a number of important and novel discoveries in the past year. 1) The insulin receptor-related receptor (IRR) is a newly discovered member of the IGF receptor family whose ligand and biological role are still unknown. This lab has shown that during embryonic development, the IRR is exclusively and synchronously co-expressed with the high-affinity nerve growth factor (NGF) receptor, TRK, suggesting that these two receptors are physically or functionally linked in determining the survival of sensory and sympathetic neurons - and that the IRR ligand is likely to be a novel neurotrophin. 2) The section has provided the first evidence that IGFs-I and -II cross the blood brain barrier with potency at least ten-fold greater than insulin, suggesting that systemic IGF levels may play an important role in relaying information concerning peripheral metabolic-nutritional status to brain regulatory centers. 3) The group has shown that production of components of the high molecular weight IGF binding complex, which is responsible for maintaining stable IGF levels in the circulation - is segregated into distinct hepatic cellular compartments which are differentially regulated by growth hormone. 4) of great importance for women's reproductive health, we have found that IGF-I appears to stimulate endometrial growth in the follicular phase of the menstrual cycle, while IGF-II appears to trigger endometrial decidualization in the secretory phase. These findings have very significant clinical implications in terms of the potential utilization of IGFs to selectively stimulate anabolic processes in the nervous and reproductive systems.
| Hadnott, Tracy N; Gould, Harley N; Gharib, Ahmed M et al. (2011) Outcomes of spontaneous and assisted pregnancies in Turner syndrome: the U.S. National Institutes of Health experience. Fertil Steril 95:2251-6 |
| Bakalov, Vladimir K; Cheng, Clara; Zhou, Jian et al. (2009) X-chromosome gene dosage and the risk of diabetes in Turner syndrome. J Clin Endocrinol Metab 94:3289-96 |
| Bondy, Carolyn A (2009) Turner syndrome 2008. Horm Res 71 Suppl 1:52-6 |
| McCarthy, Kateri; Bondy, Carolyn A (2008) Turner syndrome in childhood and adolescence. Expert Rev Endocrinol Metab 3:771-775 |
| Matura, Lea Ann; Ho, Vincent B; Rosing, Douglas R et al. (2007) Aortic dilatation and dissection in Turner syndrome. Circulation 116:1663-70 |
| Bondy, Carolyn A; Turner Syndrome Study Group (2007) Care of girls and women with Turner syndrome: A guideline of the Turner Syndrome Study Group. J Clin Endocrinol Metab 92:10-25 |
| Matura, Lea Ann; Sachdev, Vandana; Bakalov, Vladimir K et al. (2007) Growth hormone treatment and left ventricular dimensions in Turner syndrome. J Pediatr 150:587-91 |
| Bondy, Carolyn A; Matura, Lea Ann; Wooten, Nicole et al. (2007) The physical phenotype of girls and women with Turner syndrome is not X-imprinted. Hum Genet 121:469-74 |
| King, Kelly A; Makishima, Tomoko; Zalewski, Christopher K et al. (2007) Analysis of auditory phenotype and karyotype in 200 females with Turner syndrome. Ear Hear 28:831-41 |
| Bondy, C A (2007) Heart disease in Turner syndrome. Minerva Endocrinol 32:245-61 |
Showing the most recent 10 out of 77 publications
